Previous 10 | Next 10 |
Cerus (NASDAQ: CERS ): Q3 GAAP EPS of -$0.13 misses by $0.01 . More news on: Cerus Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2019. Recent developments and highlights include: FDA issued its final guidance document on strategies to mitigate the risk of bacterial contamination in transfused platelet ...
AAPL , ACA , ACAD , ADTN , AGI , AGNC , AKS , ALEX , ALSN , APA , ARES , ATRC , AWK , AXTI , AZPN , BFAM , BLDP , BOOT , CACI , CATM , CERS , CF , CHDN , CHEF , CLI , CLR , CMPR , CNMD , CNXN , COLM , CONE , CREE , CRUS , CRY , CSGS , CTSH , CW , DDD , ...
Cerus Corporation (Nasdaq:CERS) announced today that its third quarter 2019 results will be released on Wednesday, October 30, 2019, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss th...
Cerus Corporation (Nasdaq:CERS) announced today its schedule of key events and presentations at the 2019 AABB Annual Meeting which is taking place in San Antonio, Texas on October 19 th through October 22 nd . The AABB Annual Meeting is one of the largest scientific symposiums focused on...
Small-cap stocks have been weighed down by ongoing uncertainty associated with trade deals and interest rate policy, making it harder than ever to spot potential winners and limit risk. Although small-cap stocks could face headwinds if the economy decelerates, there are specific industries and...
Small-cap stocks have underperformed large-cap stocks, and recent manufacturing and services industry data increases concerns that profits could stagnate. The risk of decelerating economic activity to small-cap stocks shouldn't be ignored, but that doesn't mean there aren't sectors, industries...
Cerus Corporation (Nasdaq: CERS) applauds the publication of the FDA final guidance document titled Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Guidance for Industry . The ...
Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus’ vice president, finance and chief financial officer will present and provide a corporate update at the 2019 Cantor Global Healthcare Conference in New York City on Wednesday, October 2, 2019 at 3:00 p.m. ET. ...
Cerus Corporation (Nasdaq: CERS) today announced that the Company will participate in two upcoming investor conferences. William ‘Obi’ Greenman, Cerus’ president and chief executive officer, is scheduled to present at the Baird 2019 Global Healthcare Conference on W...
News, Short Squeeze, Breakout and More Instantly...
Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discu...
Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain an...
Symposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and LED Illuminator Programs Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38 th...